Alluvi, previously BI 4744, represents a promising breakthrough in weight control therapy. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors https://bookmarkfavors.com/story7872970/alluvi-a-comprehensive-investigation-into-the-medication-s-potential